Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunologic nonresponsiveness to tumors

S J Antonia1, M Extermann, R A Flavell

  • 1Division of Medical Oncology, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA.

Critical Reviews in Oncogenesis
|October 1, 1998
PubMed
Summary

Tumor cells evade immune responses through mechanisms like immune deviation and anergy, hindering T cell effectiveness. Understanding these evasion tactics is key to developing better cancer immunotherapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Murine Mesenteric Lymphadenectomy for Selective Disruption of Lymphatic Communication with Region-Specific Gut.

Journal of visualized experiments : JoVE·2026
Same author

Murine Bilateral Renal Lymphadenectomy.

Journal of visualized experiments : JoVE·2026
Same author

T Cell Receptors for Antigen on Intraepitheial Cytolytic T Lymphocytes in Celiac Disease Engage Enterocyte HLA-E and HLA-B.

bioRxiv : the preprint server for biology·2025
Same author

Phase I study of peposertib and avelumab with or without palliative radiotherapy in patients with advanced solid tumors.

ESMO open·2024
Same author

A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations.

ESMO open·2023
Same author

Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial.

ESMO open·2022

Area of Science:

  • Immunology
  • Oncology
  • Cancer Research

Background:

  • Malignant cells express tumor-associated antigens, eliciting T cell responses.
  • Despite T cell recognition, tumors are often not rejected effectively.
  • T cell tolerance can be induced via immune deviation, anergy, or activation-induced cell death (AICD).

Purpose of the Study:

  • To explore the mechanisms by which T cells fail to reject tumors.
  • To investigate how tumor cells actively interfere with anti-tumor immune responses.
  • To identify potential strategies for enhancing cancer immunotherapy.

Main Methods:

  • Review of existing literature on T cell tolerance and tumor immune evasion.
  • Analysis of known mechanisms of immune evasion employed by tumor cells.
  • Synthesis of information regarding T cell dysfunction in the tumor microenvironment.

Main Results:

  • Tumor cells can evade T cell-mediated killing through various immunosuppressive strategies.
  • Mechanisms include down-regulation of MHC molecules, secretion of TGF-beta, and expression of Fas ligand.
  • T cell unresponsiveness can result from immune deviation, anergy induction, and AICD.

Conclusions:

  • Understanding tumor immune evasion is crucial for improving cancer immunotherapy.
  • Targeting these evasion mechanisms may restore anti-tumor T cell activity.
  • Further research into tumor-host interactions can guide novel therapeutic approaches.

Related Experiment Videos